G J L Kaspers

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. pmc A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges
    Annelies Overbeek
    Department of Paediatrics, Division of Paediatric Oncology Haematology, VU University Medical Center, PO Box 7057, Amsterdam, 1007MB, The Netherlands
    BMC Cancer 12:363. 2012
  2. doi request reprint Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group
    Gertjan J L Kaspers
    Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117, NL 1081HV Amsterdam, The Netherlands
    J Clin Oncol 31:599-607. 2013
  3. pmc Alpe d'HuZes cancer rehabilitation (A-CaRe) research: four randomized controlled exercise trials and economic evaluations in cancer patients and survivors
    Mai J M Chinapaw
    Department of Public and Occupational Health, EMGO Institute for Health and Care Research, VU University Medical Center, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands
    Int J Behav Med 19:143-56. 2012
  4. doi request reprint Pediatric acute myeloid leukemia
    Gertjan J L Kaspers
    Department of Pediatric Oncology Hematology of the VU University Medical Center, De Boelelaan 1117, NL 1081, HV Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 12:405-13. 2012
  5. pmc Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases
    Harm C A Graat
    Department of Orthopedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Mol Cancer 7:9. 2008
  6. pmc Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study
    Raphaele R L van Litsenburg
    Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands
    Health Qual Life Outcomes 9:25. 2011
  7. pmc Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study
    Machteld A G de Vries
    Department of Paediatrics and Division of Oncology Haematology, VU University Medical Centre, Amsterdam, The Netherlands
    Health Qual Life Outcomes 6:103. 2008
  8. pmc The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study
    Jaap Huisman
    Department of Medical Psychology, VU University Medical Center, P, O, Box 7057, 1007 MB Amsterdam, The Netherlands
    BMC Pediatr 8:25. 2008
  9. pmc Ethical issues at the interface of clinical care and research practice in pediatric oncology: a narrative review of parents' and physicians' experiences
    Martine C de Vries
    Department of Pediatrics, Leiden University Medical Center, J6 S, PO Box 9600, 2300 RC Leiden, The Netherlands
    BMC Med Ethics 12:18. 2011
  10. pmc WEE1 inhibition sensitizes osteosarcoma to radiotherapy
    Jantine Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    BMC Cancer 11:156. 2011

Detail Information

Publications86

  1. pmc A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges
    Annelies Overbeek
    Department of Paediatrics, Division of Paediatric Oncology Haematology, VU University Medical Center, PO Box 7057, Amsterdam, 1007MB, The Netherlands
    BMC Cancer 12:363. 2012
    ....
  2. doi request reprint Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group
    Gertjan J L Kaspers
    Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117, NL 1081HV Amsterdam, The Netherlands
    J Clin Oncol 31:599-607. 2013
    ..These considerations led to a randomized phase III study by the International Berlin-Frankfurt-Münster Study Group...
  3. pmc Alpe d'HuZes cancer rehabilitation (A-CaRe) research: four randomized controlled exercise trials and economic evaluations in cancer patients and survivors
    Mai J M Chinapaw
    Department of Public and Occupational Health, EMGO Institute for Health and Care Research, VU University Medical Center, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands
    Int J Behav Med 19:143-56. 2012
    ..However, many previous studies had methodological weaknesses related to trial design, sample size, comparison group, outcome measures, short follow-up durations and programme content...
  4. doi request reprint Pediatric acute myeloid leukemia
    Gertjan J L Kaspers
    Department of Pediatric Oncology Hematology of the VU University Medical Center, De Boelelaan 1117, NL 1081, HV Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 12:405-13. 2012
    ..Therefore, optimism is justified and the treatment of pediatric AML will continue to improve...
  5. pmc Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases
    Harm C A Graat
    Department of Orthopedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Mol Cancer 7:9. 2008
    ..These findings suggest that systemic administration of Ad5-Delta24RGD might be a promising new treatment strategy for metastatic osteosarcoma...
  6. pmc Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study
    Raphaele R L van Litsenburg
    Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands
    Health Qual Life Outcomes 9:25. 2011
    ..In general, sleep problems can lead to significant morbidity and are associated with impaired QoL. Information on sleep is essential to develop interventions to improve QoL...
  7. pmc Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study
    Machteld A G de Vries
    Department of Paediatrics and Division of Oncology Haematology, VU University Medical Centre, Amsterdam, The Netherlands
    Health Qual Life Outcomes 6:103. 2008
    ..The present study was performed to assess the effect of dexamethasone on QoL during treatment for ALL according to this protocol...
  8. pmc The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study
    Jaap Huisman
    Department of Medical Psychology, VU University Medical Center, P, O, Box 7057, 1007 MB Amsterdam, The Netherlands
    BMC Pediatr 8:25. 2008
    ....
  9. pmc Ethical issues at the interface of clinical care and research practice in pediatric oncology: a narrative review of parents' and physicians' experiences
    Martine C de Vries
    Department of Pediatrics, Leiden University Medical Center, J6 S, PO Box 9600, 2300 RC Leiden, The Netherlands
    BMC Med Ethics 12:18. 2011
    ..This paper discusses the ethical consequences of the unprecedented integration of research and care in pediatric oncology from the perspective of parents and physicians...
  10. pmc WEE1 inhibition sensitizes osteosarcoma to radiotherapy
    Jantine Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    BMC Cancer 11:156. 2011
    ..Inhibition of WEE1 kinase leads to abrogation of the G(2) arrest and could sensitize OS cells to irradiation induced cell death...
  11. pmc Design of the Quality of Life in Motion (QLIM) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a combined physical exercise and psychosocial training program to improve physical fitness in children with cancer
    Katja I Braam
    Department of Paediatrics, Division of Oncology Haematology, VU University Medical Center, Amsterdam, The Netherlands
    BMC Cancer 10:624. 2010
    ..Also examined is whether positive effects on physical fitness reduce inactivity-related adverse health problems, improve quality of life, and are cost-effective...
  12. ncbi request reprint Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML
    G J L Kaspers
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands, and Department of Pediatric Hematology Oncology, Children s Medical Hospital, University of Bonn, Germany
    Pediatr Blood Cancer 47:539-42. 2006
    ....
  13. ncbi request reprint 6th International Symposium and expert workshops on Leukemia and Lymphoma. 17-19 March, 2005, Amsterdam, The Netherlands
    Gertjan J L Kaspers
    Division of Oncology Hematology, Department of Pediatrics, VU University Medical Center, De Boelelaan 1117, NL 1081 HV Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 5:415-7. 2005
  14. ncbi request reprint Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia
    Gertjan J L Kaspers
    Department of Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117, NL 1081 HV Amsterdam, The Netherlands
    Eur J Cancer 41:1300-3. 2005
    ..These results do not explain the relatively poor prognosis of T-cell ALL at relapse, but do suggest that the more intensive use of thiopurines in relapsed T-cell ALL may be beneficial...
  15. ncbi request reprint Pediatric acute myeloid leukemia: towards high-quality cure of all patients
    Gertjan J L Kaspers
    Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117 NL 1081 HV Amsterdam, The Netherlands
    Haematologica 92:1519-32. 2007
    ....
  16. ncbi request reprint Clinical significance of cellular drug resistance in childhood leukemia
    G J L Kaspers
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    Recent Results Cancer Res 161:196-220. 2003
    ..The data are more and more being used and being considered for use in clinical trials in leukemia...
  17. pmc The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
    I Hubeek
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan 1117, Postbus 7057, 1007 MB, Amsterdam, The Netherlands
    Br J Cancer 93:1388-94. 2005
    ..29; 0.04). In conclusion, decreased expression of hENT1, which transports ara-C across the cell membrane, appears to be a major factor in ara-C resistance in childhood AML...
  18. ncbi request reprint Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line
    I Hubeek
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Nucleosides Nucleotides Nucleic Acids 23:1513-6. 2004
    ..29 +/- 0.11). In conclusion, in this in vitro study we showed that the cytotoxicity of ara-C can be succesfully modulated in the HL60 cell line by cladribine and gemcitabine...
  19. ncbi request reprint Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells
    A D Adema
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Nucleosides Nucleotides Nucleic Acids 25:981-6. 2006
    ..The patient samples showed a large range of sensitivity to troxacitabine, similar to other deoxynucleoside analogues. Cross-resistance with all other deoxynucleoside analogues was observed...
  20. pmc Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours
    I Hubeek
    Department of Paediatric Haematology Oncology, VU University Medical Centre, De Boelelaan 1117, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    J Clin Pathol 58:695-9. 2005
    ..Deoxycytidine kinase (dCK) is responsible for the activation of several clinically important deoxynucleoside analogues used for the treatment of haematological and solid malignancies...
  21. doi request reprint Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials
    A Sander
    Department of Pediatric Hematology Oncology, Medical School Hannover, Hannover, Germany
    Leukemia 24:1422-8. 2010
    ..0001). Overall, one-third of children with relapsed AML can be cured today. SCT in CR2 is recommended for most patients, although its impact on CR2 is discussed...
  22. ncbi request reprint Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
    B F Goemans
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 19:1536-42. 2005
    ..Our results demonstrate that abnormalities of signal transduction pathways are frequent in pediatric AML. Future clinical studies are needed to determine whether selective targeting of these abnormalities will improve treatment results...
  23. doi request reprint Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples
    I Hubeek
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Nucleosides Nucleotides Nucleic Acids 27:787-93. 2008
    ..In NSCLC and normal tissues expression of hENT1 and hCNT1 ranged from completely negative to high. Immunohistochemistry might be a useful tool to predict response to deoxynucleoside analogs in malignancies treated with these drugs...
  24. doi request reprint Circumvention of glucocorticoid resistance in childhood leukemia
    E G Haarman
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Leuk Res 32:1417-23. 2008
    ..Meta-iodobenzylguanidine however, partially reversed glucocorticoid resistance in 19% of the lymphoblastic leukemia samples...
  25. doi request reprint EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia
    B V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 24:942-9. 2010
    ..Further research should explain the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML...
  26. ncbi request reprint Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia
    I Hubeek
    Department of Paediatric Haematology Oncology, VU University Medical Centre, Amsterdam, The Netherlands
    Br J Haematol 131:219-22. 2005
    ..In conclusion, favourable interactions were observed between ara-C and aphidicolin, cladribine, gemcitabine and also with flavopiridol and UCN-01, supporting the evaluation of these combinations in clinical trials with AML patients...
  27. ncbi request reprint Treatment of childhood acute myeloid leukemia
    Edske ter Bals
    Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117, NL 1081 HV, Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 5:917-29. 2005
    ....
  28. ncbi request reprint Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity
    I Hubeek
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Nucleosides Nucleotides Nucleic Acids 23:1351-6. 2004
    ..In conclusion, dCK expression varies between individual samples and between different types of malignancies and may play a role in resistance to ara-C in particular tumor types...
  29. ncbi request reprint Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment
    J H Hooijberg
    Department of Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 58:1-12. 2006
    ....
  30. ncbi request reprint Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
    J Cloos
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 20:1217-20. 2006
    ..Fms-like tyrosine kinase 3/ITD is a relevant marker for prognosis, and remains an important target for therapeutic inhibition...
  31. ncbi request reprint CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo
    I Hubeek
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Oncol Rep 19:1517-23. 2008
    ..This study demonstrates favorable in vitro and in vivo interactions between CI-994 and conventional anti-cancer agents used for the treatment of AML...
  32. doi request reprint The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
    C Bachas
    Department of Pediatric Oncology Hematology, Amsterdam, The Netherlands
    Leukemia 26:1313-20. 2012
    ..These results imply that early detection of pre-existing drug-resistant leukemic subpopulations is crucial for relapse prevention by proper timing of targeted treatment...
  33. doi request reprint Validity of self-reported data on pregnancies for childhood cancer survivors: a comparison with data from a nationwide population-based registry
    A Overbeek
    Division of Pediatric Oncology Hematology, Department of Pediatrics, VU University Medical Center, PO Box 7057, Amsterdam 1000 MB, The Netherlands
    Hum Reprod 28:819-27. 2013
    ..To what degree do records registered in the Netherlands Perinatal Registry (PRN) agree with self-report in a study questionnaire on pregnancy outcomes in childhood cancer survivors (CCSs)?..
  34. ncbi request reprint Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia
    C M Zwaan
    Department of Paediatric Haematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Br J Haematol 127:264-79. 2004
    ..International collaboration is needed to further improve outcome by developing treatment protocols for subgroups of paediatric AML...
  35. ncbi request reprint Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia
    E G Haarman
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan, Amsterdam, The Netherlands
    Leukemia 18:530-7. 2004
    ..The association between GRgamma expression and in vitro GC resistance in iALL and the decreased protein/mRNA ratio in rALL, a subgroup resistant to GCs, warrants further exploration...
  36. ncbi request reprint The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia
    Isabelle Hubeek
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Oncol 25:1823-9. 2004
    ..Pre-exposure to G-CSF before FLA (FLAG) did not result in increased cytotoxicity in our experiments, indicative of similar anti-leukemic activity...
  37. doi request reprint High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome
    B V Balgobind
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Leukemia 24:2048-55. 2010
    ..Although further investigation for the role of BRE in leukemogenesis and outcome is warranted, high BRE expression is an independent prognostic factor for pRFS in pediatric AML...
  38. ncbi request reprint Proteasome inhibition as novel treatment strategy in leukaemia
    J Vink
    Department of Paediatric Oncology Haematology, VU University Medical Centre, De Boelelaan, Amsterdam, The Netherlands
    Br J Haematol 134:253-62. 2006
    ..This review summarises the biological and clinical aspects of proteasome inhibition and discusses the potential role of these inhibitors in the treatment of leukaemia...
  39. ncbi request reprint Online fluorescent method to assess BCRP/ABCG2 activity in suspension cells
    J H Hooijberg
    Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Nucleosides Nucleotides Nucleic Acids 23:1451-4. 2004
    ..8226/MR cells displayed a larger cellular efflux rate of the BCRP substrate Hoechst 33342, as compared to the wildtype cells. This difference in efflux rate was completely decreased in the presence of the BCRP inhibitor Ko143...
  40. ncbi request reprint In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development
    D Bresters
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 17:1338-43. 2003
    ..In conclusion, we show that aplidin has selective cytotoxicity in vitro towards childhood leukemia cells and generally lacks crossresistance with other known cytotoxic drugs, which warrants clinical studies...
  41. doi request reprint FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657
    Bianca F Goemans
    Pediatric Oncology and Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Res 34:1302-7. 2010
    ..Further clinical evaluation of SU11657 and sunitinib combined with chemotherapy would be of interest. Inclusion in clinical trials should not be restricted to patients with FLT3 or KIT mutations...
  42. ncbi request reprint Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
    Christian M Zwaan
    Department of Pediatric Hematology Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Blood 99:245-51. 2002
    ..It was concluded that the better prognosis of DS AML might, at least partially, be explained by a specific, relatively sensitive drug-resistance profile, reflecting the unique biology of this disease. (Blood. 2002;99:245-251)..
  43. ncbi request reprint In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia
    Isabelle Hubeek
    Dept of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Haematologica 91:17-23. 2006
    ..Cytarabine (ara-C) is a key drug in the treatment of acute leukemia. Resistance to ara-C might be circumvented by the use of other deoxynucleoside analogs...
  44. ncbi request reprint In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
    Bianca F Goemans
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Blood 106:3532-7. 2005
    ..Future studies are needed to identify biomarkers predictive of tipifarnib sensitivity. In addition, clinical studies, especially in T-cell ALL, seem warranted...
  45. ncbi request reprint Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities
    Christian M Zwaan
    Department of Pediatric Hematology Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Blood 100:3352-60. 2002
    ..We conclude that some, but not all, cytogenetic subgroups in childhood AML display specific drug-resistance profiles...
  46. ncbi request reprint The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis
    Jan Hendrik Hooijberg
    Department of Pediatric Hematology Oncology, VU University Medical Center VUmc, De Boelelaan 1117, 1007 MB, Amsterdam, The Netherlands
    Biochem Pharmacol 65:765-71. 2003
    ..These results suggest that down- and up-regulation of MRP1 (and MRP3) expression can influence cellular folate homeostasis, in particular when cellular retention by polyglutamylation of folates is attenuated...
  47. ncbi request reprint Past, current and future protocols for combined modality therapy in childhood medulloblastoma
    Patricia Kaaijk
    VU University Medical Center, Dept Pediatric Hematology Oncology, Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 3:79-90. 2003
    ..This review will evaluate past, current and future treatment approaches of combined modality therapy in childhood medulloblastoma...
  48. ncbi request reprint FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
    Christian M Zwaan
    Department of Pediatric Hematology Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Blood 102:2387-94. 2003
    ..However, poor outcomes in FLT3/ITD-positive patients could not be attributed to increased in vitro cellular drug resistance...
  49. ncbi request reprint Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1)
    Jan Hendrik Hooijberg
    Department of Pediatric Hematology Oncology, VU University Medical Center VUmc, De Boelelaan 1117, 1007 MB, Amsterdam, The Netherlands
    Biochem Pharmacol 67:1541-8. 2004
    ..These results have potentially important implications in the understanding of the (patho-)physiological roles of MRP1/ABCC1, and possibly other ABC transporter proteins in cellular folate homeostasis and drug resistance...
  50. ncbi request reprint Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis
    Christian M Zwaan
    Department of Pediatric Hematology Oncology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
    Blood 101:3868-71. 2003
    ..Further studies are needed to determine the efficacy and safety of GO in children with AML...
  51. doi request reprint Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology
    M H A Jansen
    Department of Pediatrics, Division of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Treat Rev 38:27-35. 2012
    ..Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease...
  52. pmc Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia
    P Kaaijk
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Br J Cancer 88:775-81. 2003
    ..In conclusion, cell proliferation differs between leukaemia subgroups and increased proliferation is associated with increased in vitro sensitivity to several anticancer agents in initial ALL...
  53. ncbi request reprint Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia
    C J Hess
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol 30:299-306. 2008
    ..e. methylation of FANCF in cell line CHRF-288. We investigated the presence of aberrant methylation in 11 FA-BRCA genes in sporadic cases of leukaemia...
  54. pmc Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
    J Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Clin Exp Metastasis 28:493-503. 2011
    ....
  55. doi request reprint Strategies for the analysis of in vitro radiation sensitivity and prediction of interaction with potential radiation modifying agents
    Mark Luttjeboer
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Radiat Biol 86:458-66. 2010
    ..The aim of this article is to show that both clonogenic capacity and cellular proliferation, which represent important different elements of tumour conduct, can be considered when assessing in vitro radio sensitisation...
  56. ncbi request reprint Congenital leukaemia: the Dutch experience and review of the literature
    Dorine Bresters
    Department Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Br J Haematol 117:513-24. 2002
    ..Once complete remission is achieved, patients with AML fare better than those with ALL. Chemotherapy for congenital leukaemia needs improvement to increase the sustained remission rate...
  57. doi request reprint Implementation of a multi-institutional diffuse intrinsic pontine glioma autopsy protocol and characterization of a primary cell culture
    V Caretti
    Department of Pediatric Oncology Neurosurgical Center Amsterdam Neuro oncology Research Group Department of Pathology Department of Clinical Genetics, VU University Medical Center, Amsterdam Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Neuropathol Appl Neurobiol 39:426-36. 2013
    ....
  58. doi request reprint Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
    N E Franke
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leukemia 26:757-68. 2012
    ..Our findings further suggest that second-generation proteasome inhibitors that target the α7 subunit of the proteasome can overcome this drug resistance modality...
  59. pmc Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
    H C A Graat
    Department of Orthopedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Br J Cancer 94:1837-44. 2006
    ..In general, our work underscores the importance of testing new genetic anticancer agents and treatment regimens on primary cancer specimens...
  60. ncbi request reprint Psychosexual functioning of childhood cancer survivors
    E M van Dijk
    Department of Medical Psychology, VU University Medical Center, Amsterdam, The Netherlands
    Psychooncology 17:506-11. 2008
    ..The objective of the study is to explore psychosexual functioning and its relationship with quality of life in survivors of cancer in childhood...
  61. pmc Surgical morbidity and mortality of pediatric brain tumors: a single center audit
    F W Neervoort
    Neurosurgical Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    Childs Nerv Syst 26:1583-92. 2010
    ..Secondly, this study aims to contribute to the accumulating data concerning outcome in pediatric neurosurgery, in order to establish institutional practice benchmarks...
  62. ncbi request reprint Use of the differential staining cytotoxicity assay to predict chemosensitivity
    Gertjan J L Kaspers
    Department of Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, Netherlands
    Methods Mol Med 110:49-57. 2005
    ..This chapter describes the practical aspects of this assay, several topics that need to be taken into account, and potential pitfalls. As such, it is not an extensive review of studies in which the DiSC assay was used...
  63. pmc Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment
    Dannis G van Vuurden
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    PLoS ONE 4:e5953. 2009
    ..This commonly results in Na(+) and Ca(2+)-permeability and thereby in excitotoxic cell death of the surrounding neurons. Here we investigated how the GBM cells themselves survive in a glutamate-rich environment...
  64. doi request reprint Psychiatric symptoms causing delay in diagnosing childhood cancer: two case reports and literature review
    T B Hensgens
    Department of Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Eur Child Adolesc Psychiatry 22:443-50. 2013
    ..A literature survey was performed including patients under 18 years of age with psychiatric symptoms in whom later on an oncological diagnosis became evident as an explanation...
  65. doi request reprint Pyuria is absent during urinary tract infections in neutropenic patients
    I L M Klaassen
    Department of Pediatric Oncology Hematology, VU Medical Center, Amsterdam, The Netherlands
    Pediatr Blood Cancer 56:868-70. 2011
    ..Urinary tract infection was defined as ≥10(5) urinary pathogens in the absence of another focus. Pyuria was found in only 1/23 neutropenic episodes compared to 21/31 in controls (P < 0.0001)...
  66. doi request reprint High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
    Costa Bachas
    Department of Pediatric Oncology Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Blood 116:2752-8. 2010
    ..We hence propose that risk stratification, malignant cell detection, and selection of personalized treatment should be based on status of type I/II mutations both at initial diagnosis and during follow-up...
  67. ncbi request reprint A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor
    Jan E Carette
    Department of Medical Oncology, Gene Therapy Division, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Virology 361:56-67. 2007
    ..Our method to modify adenovirus tropism might thus be useful to design new oncolytic adenoviruses for more effective treatment of cancer...
  68. ncbi request reprint Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53
    Harm C A Graat
    Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    Mol Cancer Ther 6:1552-61. 2007
    ..These findings suggest that Nutlins are promising compounds to be combined with p53 gene therapy and oncolytic virotherapy for cancer...
  69. pmc In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma
    Shahryar E Mir
    Neuro oncology Research Group, Departments of Neurosurgery and Pediatric Oncology Hematology, VU University Medical Center, 1081 HV, Amsterdam, The Netherlands
    Cancer Cell 18:244-57. 2010
    ..Our results suggest that inhibition of WEE1 kinase holds potential as a therapeutic approach in treatment of glioblastoma...
  70. ncbi request reprint Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs)
    Mahban Irandoust
    Department of Pediatric Oncology Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
    Anticancer Agents Med Chem 9:212-20. 2009
    ..Since SHPs have been linked to many different malignancies, protein tyrosine phosphatases could offer a great spectrum of new, targeted drugs...
  71. doi request reprint A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia
    Denise Niewerth
    Department of Pediatric Oncology Hematology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Blood 116:2205-14. 2010
    ..Further research should focus on the possibility that subgroups might benefit from allo-SCT, aiming at further improvements in the prognosis of pediatric AML...
  72. ncbi request reprint Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids
    Ruud Oerlemans
    VU University Medical Center, Amsterdam, The Netherlands
    Arthritis Rheum 54:557-68. 2006
    ..To explore the onset and molecular mechanism of resistance to the antimalarial disease-modifying antirheumatic drug (DMARD) chloroquine (CQ) in human CEM T cells...
  73. pmc Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis
    Ruud Oerlemans
    Department of Rheumatology, Room 4A42, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Ann Rheum Dis 66:1289-95. 2007
    ..The availability of drugs that could modulate GC resistance is therefore of potential clinical interest...
  74. pmc Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
    Brian V Balgobind
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 114:2489-96. 2009
    ..Screening for these translocation partners is needed for accurate treatment stratification at diagnosis...
  75. doi request reprint Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia
    Iris H I M Hollink
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 113:5951-60. 2009
    ..001). Patients with both a WT1 mutation and a FLT3/ITD had a dismal prognosis (5-year pOS 21%). WT1 mutations occur at a significant rate in childhood AML and are a novel independent poor prognostic marker...
  76. doi request reprint Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia
    Hendrik J M de Jonge
    Division of Pediatric Oncology Hematology, Department of Pediatrics, Beatrix Children s Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Clin Cancer Res 14:924-30. 2008
    ....
  77. doi request reprint Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia
    Ilan J N Koppen
    Department of Paediatric Oncology Haematology, VU University Medical Center, Amsterdam, The Netherlands
    Br J Haematol 148:3-14. 2010
    ..Further investigations on the relevance of these polymorphisms need to be performed. In general, it is clear that susceptibility to (childhood) ALL is partly related to constitutional differences in folate gene polymorphisms...
  78. doi request reprint High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia
    Hendrik J M de Jonge
    Division of Pediatric Oncology Hematology, Department of Pediatrics, Beatrix Children s Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Blood 116:1747-54. 2010
    ..In conclusion, high VEGFC predicts adverse long-term prognosis and provides prognostic information in addition to well-known prognostic factors...
  79. ncbi request reprint Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia
    Robert de Jonge
    Department of Clinical Chemistry and Pediatric Oncology Hematology, Erasmus MC, Rm L 102, POB 2040, 3000 CA Rotterdam, The Netherlands
    Blood 106:717-20. 2005
    ..SHMT1 1420TT homozygotes only showed decreased MTX sensitivity in the TSI(50, cont). In conclusion, polymorphisms in the folate-related genes MTHFR, MTRR, and SHMT1 are related to MTX resistance in pediatric patients with ALL...
  80. ncbi request reprint Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses
    Harm C A Graat
    Clin Cancer Res 11:2445-7; author reply 2447-8. 2005
  81. ncbi request reprint A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia
    Bernard M Fine
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System and Department of Medicine, Palo Alto, CA, USA
    Cancer Res 65:291-9. 2005
    ..These results suggest that targeting particular genes involved in the response to amino acid starvation in ALL cells may provide a novel way to overcome l-asparaginase resistance...
  82. ncbi request reprint Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Blood 109:4641-7. 2007
    ..Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having a major prognostic impact which should be reflected in future risk-group stratification...
  83. ncbi request reprint Medulloblastoma: need for targeted treatment
    Mark Luttjeboer
    Expert Rev Anticancer Ther 6:649-52. 2006
  84. ncbi request reprint Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia?
    Christian Michel Zwaan
    Blood 107:4975-6; author reply 4976-7. 2006
  85. ncbi request reprint Targeted monoclonal antibody-based treatment of hematological malignancies
    Gertjan J L Kaspers
    Expert Rev Anticancer Ther 3:253-5. 2003
  86. pmc Clinical implications of FLT3 mutations in pediatric AML
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Clinical Research Division, D5 380, 1100 Fairview Ave N, Seattle, WA 98103, USA
    Blood 108:3654-61. 2006
    ..001) or with FLT3/WT (55%, P < .001). ITD-AR defines the prognostic significance in FLT3/ITD-positive AML, and ITD-AR greater than 0.4 is a significant and independent prognostic factor for relapse in pediatric AML...